Quick Dispatch:
Your tirzepatide surpass-5 Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan ( SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial - orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass-5 Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan ( SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial - ships.
Need Help?
Questions about tirzepatide surpass-5 Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan ( SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial -, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass-5 Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan ( SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial - in your area.
Tirzepatide: First Approval | Drugs
20.15
Results of SURPASS-1-5 for tirzepatide treatment in T2D
25.32
Dual GIP/GLP-1 receptor agonist as an innovative therapeutic option
23.09
SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs
23.10
SURPASS-5 Data: Tirzepatide Plus Insulin Glargine Improve Glycemic Control in T2D
26.51
SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes
22.24
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme - Bergman - 2025 - Diabetes, Obesity and Metabolism
20.69
